A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema Associated With Diabetes Mellitus

Interventions

DRUG: Standard of Care
DRUG: Macugen

Sponsor

Pfizer